In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osmotica Pharmaceuticals PLC

www.osmotica.com

Latest From Osmotica Pharmaceuticals PLC

Finance Watch: Rough US Stock Market Doesn't Stop Biopharma IPOs As Six More Go Public

October has not been kind to biotech stocks, but that hasn't stopped drug developers from launching IPOs in the US. Also, Takeda reconfigures debt ahead of Shire deal and other offerings.

Financing Business Strategies

IPO Update: Returns Sag As Seven More Biopharmas Go Public In September

The average return for the 54 drug developers that went public in the US during first three quarters of 2018 was 13.6% as of Oct. 1 versus 16.9% as of Aug. 31 for the 47 biopharma firms that launched IPOs during the first eight months of this year. September had seven new offerings after just two in August.

Financing Business Strategies

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies

Keeping Track: Apadaz Approved Without Abuse-Deterrent Label, FDA Denies Translarna Appeal, And Some Priority Reviews

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Generic Drugs
  • Therapeutic Areas
  • Dermatology
  • Gynecological, Urological
  • Neurology, Nervous System
  • Alias(es)
  • Osmotica Corp.
  • Osmotica Pharmaceuticals Ltd.
  • Osmotica Pharmaceutical Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Osmotica Pharmaceuticals PLC
  • Senior Management
  • Brian Markison, Chmn. & CEO
    Andrew Einhorn, CFO
    Tina S deVries, PhD, EVP, R&D
    James Schaub, EVP, COO
  • Contact Info
  • Osmotica Pharmaceuticals PLC
    Phone: (908) 809-1300
    400 Crossing Blvd.
    Bridgewater, NJ 08807
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register